RA Capital Management 13F holdings, Q3 2021
Holdings as of September 30, 2021 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 95 US equity positions worth $7.2bn in its Q3 2021 13F filing. The largest position was ASND at 16.3% of the reported book, followed by NVAX and CLYM. Against the Q2 2021 filing, it opened 11 new positions, added to 7 and reduced 2 among the top 50 holdings.
What did RA Capital Management own in Q3 2021? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2021 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 16.3% | $1.2bn | 7,387,900 | 9% | added |
| 2 | NVAX NOVAVAX INC | Healthcare | 6.0% | $434.9m | 2,097,794 | -18% | reduced |
| 3 | CLYM ELIEM THERAPEUTICS INC | 3.3% | $236.5m | 13,150,849 | – | new | |
| 4 | IVVD ADAGIO THERAPEUTICS INC | Healthcare | 3.1% | $225.6m | 5,340,130 | – | new |
| 5 | FORMA THERAPEUTICS HLDGS INC | 2.9% | $209.0m | 9,011,651 | 0% | held | |
| 6 | CTKB CYTEK BIOSCIENCES INC | Healthcare | 2.9% | $205.7m | 9,607,028 | – | new |
| 7 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 2.6% | $190.3m | 5,427,655 | 1% | added |
| 8 | JANX JANUX THERAPEUTICS INC | Healthcare | 2.6% | $187.5m | 8,670,644 | 0% | held |
| 9 | VOR VOR BIOPHARMA INC | 2.4% | $174.4m | 11,120,973 | 0% | held | |
| 10 | AEROVATE THERAPEUTICS INC | 2.4% | $173.4m | 8,263,982 | 0% | held | |
| 11 | ICOSAVAX INC | 2.4% | $171.0m | 5,779,347 | – | new | |
| 12 | DICE THERAPEUTICS INC | 2.4% | $170.6m | 5,208,911 | – | new | |
| 13 | CNTB CONNECT BIOPHARMA HLDGS LTD | 2.3% | $169.4m | 6,991,003 | 0% | held | |
| 14 | NKTX NKARTA INC | Healthcare | 2.2% | $155.9m | 5,605,129 | 0% | held |
| 15 | ABOS ACUMEN PHARMACEUTICALS INC | 2.0% | $145.2m | 9,770,773 | – | new | |
| 16 | TGTX TG THERAPEUTICS INC | Healthcare | 1.9% | $136.4m | 4,098,332 | 23% | added |
| 17 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.9% | $136.2m | 5,614,428 | 0% | held |
| 18 | TYRA TYRA BIOSCIENCES INC | Healthcare | 1.8% | $127.3m | 7,236,454 | – | new |
| 19 | MGNX MACROGENICS INC | Healthcare | 1.7% | $124.5m | 5,943,594 | 0% | held |
| 20 | ITEOS THERAPEUTICS INC | 1.7% | $119.3m | 4,417,259 | 0% | held | |
| 21 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.6% | $117.8m | 4,965,588 | 0% | held | |
| 22 | IMMUNOGEN INC | 1.4% | $104.4m | 18,417,458 | 0% | held | |
| 23 | PHAT PHATHOM PHARMACEUTICALS INC | 1.4% | $100.0m | 3,115,008 | 0% | held | |
| 24 | PCVX VAXCYTE INC | Healthcare | 1.4% | $98.9m | 3,896,865 | 1% | added |
| 25 | 89BIO INC | 1.3% | $97.3m | 4,965,769 | 0% | held | |
| 26 | TIL INSTIL BIO INC | 1.2% | $87.1m | 4,870,793 | 0% | held | |
| 27 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.2% | $86.4m | 1,600,000 | – | new |
| 28 | KINNATE BIOPHARMA INC | 1.1% | $82.7m | 3,593,052 | 0% | held | |
| 29 | HOWL WEREWOLF THERAPEUTICS INC | 1.0% | $73.6m | 4,291,881 | 0% | held | |
| 30 | TNYA TENAYA THERAPEUTICS INC | 1.0% | $73.3m | 3,551,508 | – | new | |
| 31 | POINT BIOPHARMA GLOBAL | 0.9% | $68.1m | 8,856,018 | – | new | |
| 32 | GHRS GH RESEARCH PLC | 0.9% | $66.5m | 3,013,957 | 1% | added | |
| 33 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 0.9% | $63.6m | 4,871,067 | 0% | held |
| 34 | RCKT ROCKET PHARMACEUTICALS INC COM | Healthcare | 0.9% | $63.0m | 2,107,149 | 0% | held |
| 35 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.9% | $61.5m | 1,377,569 | 0% | held |
| 36 | CNTA CENTESSA PHARMACEUTICALS PLC | 0.8% | $59.7m | 3,577,094 | 179% | added | |
| 37 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 0.8% | $59.3m | 2,150,404 | 0% | held |
| 38 | CYTEIR THERAPEUTICS INC | 0.8% | $58.8m | 3,350,506 | 3% | added | |
| 39 | PMVP PMV PHARMACEUTICALS INC | 0.7% | $51.0m | 1,710,265 | 0% | held | |
| 40 | ZOGENIX INC | 0.7% | $50.6m | 3,333,700 | -37% | reduced | |
| 41 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.6% | $45.6m | 2,805,045 | 0% | held |
| 42 | GRAPHITE BIO INC | 0.6% | $44.2m | 2,698,369 | 0% | held | |
| 43 | EWTX EDGEWISE THERAPEUTICS INC | 0.6% | $43.4m | 2,613,623 | 0% | held | |
| 44 | VERVE THERAPEUTICS INC | 0.6% | $41.4m | 880,284 | 0% | held | |
| 45 | GERN GERON CORP | Healthcare | 0.6% | $41.3m | 30,126,299 | 0% | held |
| 46 | ACHILLES THERAPEUTICS PLC | 0.5% | $39.1m | 5,014,687 | 0% | held | |
| 47 | RXST RXSIGHT INC | Healthcare | 0.5% | $38.7m | 3,052,796 | – | new |
| 48 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 0.5% | $38.1m | 7,775,207 | 0% | held |
| 49 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.5% | $33.7m | 1,930,322 | 0% | held | |
| 50 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.4% | $32.1m | 2,186,636 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.